STOCKHOLM, Sweden, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for the period January - September 2016. The Company will host a conference call and webcast today at 14:00 CET - details below. The full report is available on the Company's website.Jim Van heusden, CEO, comments: "During the third quarter 2016, Karolinska Development saw several of its portfolio companies secure new funds to finance the progression of their businesses toward defined value-creating milestones. Karolinska Development participated in these fundraising events directly and indirectly via KDev Investments, and was pleased to see experienced new investors leading and participating in the investor syndicates. The majority of companies in Karolinska Development's portfolio are now funded to deliver key value-generating milestones over the coming years, with additional value potential retained in divested companies. "A key highlight so far in 2016 has been Aprea's SEK 437 million financing in March, the largest ever completed by a Karolinska Development portfolio company and more broadly by any private life science company in Sweden in more than a decade. Dilaforette and Promimic also secured non-dilutive financing through new partnerships. More recently, Dilafor raised SEK 51 million with new investors including Lee's Healthcare Industry Fund and Pila AB. "We are also encouraged by the progress made by our portfolio companies in advancing their development pipelines, and presenting and publishing their latest results. "Additionally, we have attracted entrepreneurial leaders to the boards and senior management team of our companies: in October, Promimic strengthened its board through the elections of Tord Lendau as Chairman of the Board of Directors; and Håkan Krook and Patrik Sjöstrand as Non-executive Directors. In July, Umecrine Cognition announced the appointment of Dr. Bruce Scharschmidt as a new member of its Board of Directors and Senior Development Adviser. Aprea Therapeutics announced the appointment of Christian S. Schade as President and Chief Executive Officer (June 2016); and Simon Cartmell as Chairman of the Board of OssDsign (April 2016).